Su, Qiaoli
Liu, Ying
Zhang, Guogang
Xu, Li
Wang, Min
Mei, Shifang
Garon, Genevieve
Wu, Yanzhen
Lv, Qiang
Ma, Changsheng
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
https://doi.org/10.1007/s12325-023-02666-z
Funding for this research was provided by:
Sanofi; ROZEL
Article History
Received: 19 June 2023
Accepted: 23 August 2023
First Online: 28 September 2023
Declarations
:
: Min Wang, Shifang Mei, Genevieve Garon, and Yanzhen Wu are employees of Sanofi, and may hold shares and/or stock options in the company’ for the Sanofi employees. Qiaoli Su, Ying Liu, Guogang Zhang, Li Xu, Qiang Lv and Changsheng Ma all have no conflict of interests.
: The study was approved by ethics committees of all institutions (Supplementary Table S1) and conducted according to the tenets of the Declaration of Helsinki and the Good Clinical Practices. The master ethics committee at the main center (Beijing Anzhen Hospital) is Anzhen Hospital clinical study Ethic Committee (Approval number: 2020-02ID). All participants involved in this study provided written informed consent.